UCB Revises 2025 Forecast Upward
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: NASDAQ.COM
Financial Guidance Upgrade: UCB has upgraded its 2025 financial guidance, expecting revenue to exceed 7.6 billion euros, a 24% increase year-on-year, with an adjusted EBITDA margin anticipated to be over 31%.
Performance Drivers: The upgraded guidance is attributed to the continued growth of products like RYSTIGGO, ZILBRYSQ, FINTEPLA, and EVENITY, as well as the exceptional performance of BIMZELX, particularly in hidradenitis suppurativa and a favorable payer mix in the U.S.
Future Reporting: UCB plans to publish its 2025 results and provide formal financial guidance for 2026 on February 26, 2026.
Growth Confidence: The company's upgraded guidance reinforces its confidence in achieving long-term growth ambitions over the next decade.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
